Ocuphire Pharma Investor Day Presentation Deck

P 84 VEGA-1: Improvement in Functional Near Vision Nyxol+LDP had a Rapid Improvement in Near Vision to 20/32 for many Patients Percent of Subjects (%) 45% 40% 35% 30% 25% 20% 15% 10% 5% 0% 0% 7% 20/15 0% Binocular Photopic DCNVA Nyxol + LDP Improvement in Snellen Equivalent 84% 20/40 or Better Near Vision 68% 20/32 or Better Near Vision 12% 20/20 0% 23% 20/25 0% 26% 20/32 VEGA-1 Phase 2 Trial 0% Baseline 16% 20/40 33% 20/50 Snellen Acuity 11-Hour 40% 7% 20/63 $23% 0% 20/80 Source: VEGA-1 TLR Table 14.2.24.1 Percent of Subjects with Photopic DCNVA by Time Point (PP Population) 2% 0% 20/100 Visual Acuity Chart KCRHN ZKDV C HVORK RHSON KSVRH HNK CD NDVKO DHOSZ 20/32 VRNDO CZHKS 20/63 Ocuphire PHARMA

View entire presentation